Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development and validation of an individualized immune prognostic model in stage I-III lung squamous cell carcinoma.

Scientific reports - 16 Jun 2021

Yang Qi-Fan, Wu Di, Wang Jian, Ba Li, Tian Chen, Liu Yu-Ting, Hu Yue, Liu Li

Abstract excerpt

Lung squamous cell carcinoma (LUSC) possesses a poor prognosis even for stages I-III resected patients. Reliable prognostic biomarkers that can stratify and predict clinical outcomes for stage I-III resected LUSC patients are urgently needed. Based on gene expression of LUSC tissue samples from five public datasets, consisting of 687 cases, we developed an immune-related prognostic model (IPM) according to immune...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Carcinoma, Squamous Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune System

Share to Neoplasm Staging

Share to Nomograms

Share to Survival Analysis

Share to Transcriptome

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 34135424
DOI: 10.1038/s41598-021-92115-0
PMCID: PMC8209222

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development and validation of an individualized immune prognostic model in stage I-III lung squamous cell carcinoma.PMID 34135424Read ↗

Development and validation of a novel immune-related prognostic signature in lung squamous cell carcinoma patientsSemantic proximity Read ↗

Construction of a Prognostic Immune Signature for Squamous-Cell Lung Cancer to Predict Survival.Semantic proximity Read ↗

Construction and validation of an immunity-related prognostic signature for lung squamous cell carcinomaSemantic proximity Read ↗

Analysis of Clinical Implications and Immune Landscape in Prognostic Model based on Immune Cell Signatures for Lung Adenocarcinoma PatientsSemantic proximity Read ↗

Immune signature-based risk stratification and prediction of immune checkpoint inhibitor's efficacy for lung adenocarcinoma.Semantic proximity Read ↗

A Novel Immune-Related Seventeen-Gene Signature for Predicting Early Stage Lung Squamous Cell Carcinoma PrognosisSemantic proximity Read ↗

Development and validation of an immune‐related prognostic signature in lung adenocarcinomaSemantic proximity Read ↗

The tumor environment immune phenotype of LUSC by genome-wide analysis.Semantic proximity Read ↗

Validation of an Immune-Related Gene Pair Index as a Prognostic Marker of Lung Squamous Cell CarcinomaSemantic proximity Read ↗

A Four-gene Autophagy-related Prognostic Signature and Its Association With Immune Landscape in Lung Squamous Cell CarcinomaSemantic proximity Read ↗

Identification and validation of immune-related lncRNA prognostic signature for lung cancerSemantic proximity Read ↗

An immune gene signature to predict prognosis and immunotherapeutic response in lung adenocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.